Condition evidence map
Metabolic syndrome
Research evidence map for metabolic syndrome — the cluster of abdominal obesity, dyslipidaemia, hypertension and dysglycaemia — and the integrated effects of incretin medicines across its components.
Research context
Metabolic syndrome is a diagnostic construct rather than a single disease, with multiple criteria sets (NCEP ATP III, IDF, harmonised). It is the clinical face of insulin resistance and visceral adiposity. Incretin medicines reduce body weight, visceral fat, hepatic steatosis, blood pressure (modestly) and triglycerides in trial cohorts, hitting multiple metabolic syndrome components at once.
Why this matters metabolically
Metabolic syndrome integrates the risk pathways downstream of visceral adiposity. Trials reporting reductions across body weight, visceral fat (DXA / MRI), triglycerides and HbA1c describe a coherent metabolic-syndrome effect rather than isolated single-endpoint benefits.
FAQs
- Is metabolic syndrome an indication for incretin therapy?
- No. Metabolic syndrome is a construct that integrates several risk factors; the individual components (T2D, obesity, hypertension) are the licensed targets. Incretin medicines often improve several components together within trial cohorts.
- Component-level improvements in trials do not establish metabolic syndrome as a unified pharmacological target.
- Trial-cohort improvements do not predict individual response.
Related mechanisms
Related peptide profiles
Related trials
Related safety signals
Related conditions
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022.
- Peer-reviewed publicationWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)NICE — National Institute for Health and Care Excellence
NICE guidance on treatment pathways for metabolic conditions
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of condition profiles on this site